KRAS and pancreatic neoplasm: The downregulation of KRAS signaling was also observable in other cancer cell lines carrying different KRAS mutations, including the pancreatic cancer cell line Capan-2 (KRASG12V) (Fig. S4A), and the lung cancer cell lines H23 (KRASG12C) and A549 (KRASG12S) (Fig. S4B).